Beigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 1,402 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $252.39, for a total transaction of $353,850.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Beigene Stock Down 2.5%
Beigene stock traded down $6.90 during mid-day trading on Friday, hitting $269.63. The company had a trading volume of 391,727 shares, compared to its average volume of 451,056. The stock has a market cap of $31.92 billion, a PE ratio of -32.72, a price-to-earnings-growth ratio of 7.73 and a beta of 0.30. Beigene, Ltd. has a 1 year low of $141.31 and a 1 year high of $287.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The business has a fifty day moving average of $240.18.
Beigene (NASDAQ:ONC - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. Equities analysts anticipate that Beigene, Ltd. will post -5.82 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the stock. Royal Bank of Canada reduced their target price on shares of Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Sanford C. Bernstein set a $259.00 price target on shares of Beigene in a research note on Thursday, March 13th. Macquarie increased their price target on shares of Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Guggenheim increased their price target on shares of Beigene from $348.00 to $350.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Beigene from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Beigene presently has an average rating of "Buy" and a consensus price target of $319.00.
Check Out Our Latest Stock Analysis on Beigene
Beigene Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Featured Stories
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
